Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
25% Off Benzinga's Most Powerful Trading Tools
Traders Win More with Benzinga's Exclusive News and Squawk
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
CEL-SCI
(AMEX:CVM)
Intraday
$1.50
-0.02
[-1.32%]
Get Report
Watch
Perks
Buy
Compare Brokers
$1.50
-0.02
[-1.32%]
At close: Apr 17
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for CEL-SCI Stock (AMEX:CVM)
CEL-SCI Stock (AMEX: CVM)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, March 06, 2024
CEL-SCI Corporation Issues Letter To Shareholders
Benzinga Newsdesk
-
Mar 6, 2024, 8:47AM
Thursday, February 15, 2024
CEL-SCI Q1 EPS $(0.14) Up From $(0.18) YoY
Benzinga Newsdesk
-
Feb 15, 2024, 8:12AM
Friday, February 09, 2024
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Feb 9, 2024, 12:31PM
Why CEL-SCI Corporation (CVM) Shares Are Diving
Henry Khederian
-
Feb 9, 2024, 11:06AM
Cel-Sci shares are trading lower after the company announced pricing of a $7.75 million public offering of 3.875 million shares of common stock at $2 per share.
Benzinga Newsdesk
-
Feb 9, 2024, 10:59AM
CEL-SCI Announces Pricing Of $7.75M Public Offering Of 3.875M Shares Of Common Stock At $2.00/Share
Benzinga Newsdesk
-
Feb 9, 2024, 8:32AM
Wednesday, January 31, 2024
European Medicines Agency Grants CEL-SCI A Waiver Of Strict Pediatric Requirements, Clearing The Path Towards Marketing Authorization For Multikine
Benzinga Newsdesk
-
Jan 31, 2024, 9:18AM
Thursday, December 28, 2023
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Dec 28, 2023, 4:31PM
Friday, December 22, 2023
CEL-SCI Clocks FY23 EPS Loss of $(0.73) Vs $(0.87) YoY, Operating Loss of $(31.5)M Vs $(36.1)M YoY
Benzinga Newsdesk
-
Dec 22, 2023, 8:04AM
Monday, December 04, 2023
Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
Dec 4, 2023, 1:10PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Dec 4, 2023, 12:31PM
CEL-SCI shares are trading higher after the company announced the British National Institute for Health and Care Excellence selected the company's Multikine as a potential new standard of care for head & neck cancer.
Benzinga Newsdesk
-
Dec 4, 2023, 11:52AM
Why Is Cancer Focused CEL-SCI Stock Trading Higher Today?
Vandana Singh
-
Dec 4, 2023, 11:45AM
UK'S National Institute for Health And Care Excellence Selects CEL-SCI's Multikine As Potential New Standard of Care For Head & Neck Cancer
Benzinga Newsdesk
-
Dec 4, 2023, 8:38AM
Thursday, November 16, 2023
CEL-SCI Prices 2.49M Share Offering To A Single Investor At offering Price Of $2/Share
Benzinga Newsdesk
-
Nov 16, 2023, 8:35AM
Monday, October 30, 2023
CEL-SCI Issues Letter To Shareholders
Benzinga Newsdesk
-
Oct 30, 2023, 9:20AM
Tuesday, October 24, 2023
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans To Seek Immediate Regulatory Approvals
Benzinga Newsdesk
-
Oct 24, 2023, 8:21AM
Monday, October 23, 2023
CEL-SCI Corporation Announces 5-Year Head & Neck Cancer Survival Increased From 45% To 73% In Co's Target Population, Cutting Risk Of Death In Half, As Presented At Leading Cancer Conference ESMO 2023
Happy Mohamed
-
Oct 23, 2023, 9:16AM
Thursday, October 05, 2023
CEL-SCI Files Request With The UK's MHRA Regarding Path To Approval For Multikine In The Treatment Of Head & Neck Cancer
Benzinga Newsdesk
-
Oct 5, 2023, 8:47AM
Tuesday, September 26, 2023
Cel-Sci Submits Scientific Advice Filing To European Medicines Agency For Multikine In The Treatment Of Head And Neck Cancer
Benzinga Newsdesk
-
Sep 26, 2023, 9:25AM
Monday, August 14, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Aug 14, 2023, 1:48PM
Friday, August 11, 2023
CEL-SCI Q3 EPS $(0.19) Misses $(0.16) Estimate
Happy Mohamed
-
Aug 11, 2023, 8:06AM
Monday, August 07, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Aug 7, 2023, 12:13PM
Monday, July 31, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Jul 31, 2023, 2:54PM
Friday, July 28, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Jul 28, 2023, 12:36PM
Tuesday, July 25, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Jul 25, 2023, 12:33PM
Monday, July 24, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Jul 24, 2023, 3:48PM
Tuesday, July 18, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Jul 18, 2023, 1:31PM
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Jul 18, 2023, 1:00PM
Why CEL-SCI (CVM) Shares Are Down 20%
Henry Khederian
-
Jul 18, 2023, 11:07AM
US Stocks Mixed; Bank of America Tops Q2 Views
Lisa Levin
-
Jul 18, 2023, 9:51AM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Jul 18, 2023, 9:06AM
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Jul 18, 2023, 8:12AM
CEL-SCI shares are trading lower after the company priced its public offering of 2.5 million shares at $2/share.
Benzinga Newsdesk
-
Jul 18, 2023, 6:16AM
CEL-SCI Prices Public Offering Of 2.5M Common Shares At $2/Share
Benzinga Newsdesk
-
Jul 18, 2023, 12:41AM
Monday, July 17, 2023
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
Jul 17, 2023, 5:32PM
CEL-SCI Announces Proposed Public Offering Of Common Stock; Size Not Disclosed
Happy Mohamed
-
Jul 17, 2023, 4:07PM
Friday, July 14, 2023
CEL-SCI Concludes Meeting With U.S. FDA Concerning Multikine's Approval For Head & Neck Cancer
Happy Mohamed
-
Jul 14, 2023, 9:15AM
Wednesday, July 12, 2023
EF Hutton Reiterates Buy on CEL-SCI, Maintains $10 Price Target
Benzinga Newsdesk
-
Jul 12, 2023, 4:21AM
Tuesday, July 11, 2023
CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine's Increased Efficacy And Points To Potential For Combination With Checkpoint Inhibitors For Head And Neck Cancer
Benzinga Newsdesk
-
Jul 11, 2023, 8:46AM
Tuesday, May 16, 2023
Watching CEL-SCI; Zacks Small-Cap Research Sets $11 Price Valuation
Happy Mohamed
-
May 16, 2023, 1:05PM
Monday, May 15, 2023
Why CEL-SCI Shares Are Shooting Higher Today
Vandana Singh
-
May 15, 2023, 12:18PM
CEL-SCI Highlights Phase 3 Study Data From Histopathology And Tumor Biomarker Analysis At ESTRO 2023
Benzinga Newsdesk
-
May 15, 2023, 9:10AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
May 15, 2023, 9:06AM
Friday, May 12, 2023
CEL-SCI Q2 EPS $(0.19) Up From $(0.23) YoY
Happy Mohamed
-
May 12, 2023, 4:37PM
Tuesday, May 02, 2023
Why BlackBerry Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
May 2, 2023, 8:08AM
Monday, May 01, 2023
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
May 1, 2023, 9:06AM
Friday, April 28, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Apr 28, 2023, 1:49PM
Cel-Sci shares are trading lower after the company announced the pricing of its proposed $1.35 million public offering.
Benzinga Newsdesk
-
Apr 28, 2023, 9:09AM
Cel-Sci Priced Its Public Offering Of 794,117 Shares At $1.70/Share, For Gross Proceeds Of $1.35M
Benzinga Newsdesk
-
Apr 28, 2023, 3:42AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch